Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Prostate cancer is the most common cancer in men, excluding skin cancer. Approximately 200,000 men will be diagnosed with prostate cancer annually in the United States. Because of improved screening and advancements in treatment, outcomes continue to improve. At Weill Cornell Medical College/New York Presbyterian Hospital, we work closely with urologists and urologic medical oncologists to formulate an individualized treatment plan for each patient that is data-driven (that is, based on results of up-to-date clinical trials). We offer state of the art equipment and software to deliver the latest radiotherapy techniques, such as Image-guided Radiation therapy, Intensity Modulated Radiation Therapy (IMRT) and Brachytherapy.
We offer participation in clinical trials designed to evaluate the effectiveness of newer and promising treatments. Eligibility for these trials will be determined during the discussion of treatment options with the radiation oncologist.
For various stages of prostate cancer, there may be multiple available options, including surgical and radiotherapeutic options. We take great pride in spending time with our patients to discuss these options, allowing them to make an informed decision as to what is the best treatment for them.
The side effects you may experience will depend on the area being treated, the type of radiation used and whether or not you also received chemotherapy. Before treatment, your doctor will describe what you can expect.
Some patients experience minor or no side effects and can continue their normal routines.
If at any time you develop side effects, tell your doctor or nurse. He or she can give you medicine to help.
IRB # 1604017139 Randomized trial of image -guided stereotactic radiation therapy (IG-SRT) in prostate cancer NCT02911922
This study is currently recruiting participants.